Savara (SVRA)
(Delayed Data from NSDQ)
$3.82 USD
+0.01 (0.26%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $3.82 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.82 USD
+0.01 (0.26%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $3.82 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Zacks News
Zacks.com featured highlights include Savara, The LGL Group, and Harte Hanks
by Zacks Equity Research
Savara, The LGL Group, and Harte Hanks are part of zacks Screen of the Week article.
3 Top Breakout Stocks to Add to Your Portfolio Now
by Tirthankar Chakraborty
Savara (SVRA), LGL Group (LGL) and Harte Hanks (HHS) have been selected as the breakout stocks for today.
Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Savara Inc. (SVRA) have performed compared to their sector so far this year.
After Golden Cross, Savara Inc. (SVRA)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study
by Zacks Equity Research
Savara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis.
Implied Volatility Surging for Savara (SVRA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.
Do Options Traders Know Something About Savara (SVRA) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Savara (SVRA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.
Savara to Stop Study on Molgradex for NTM Lung Infection
by Zacks Equity Research
Savara (SVRA) to halt the ENCORE study on its lead candidate Molgradex, which was meant to treat nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis.
Savara Enters Oversold Territory
by Zacks Equity Research
Savara has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Savara Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Savara has been struggling lately, but the selling pressure may be coming to an end soon.
Is a Surprise Coming for Savara (SVRA) This Earnings Season?
by Zacks Equity Research
Savara (SVRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Are Options Traders Betting on a Big Move in Savara (SVRA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.
Company News For Oct 3, 2019
by Zacks Equity Research
Companies in the news are: SVRA, LEN, F, JNJ
The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara
Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Savara Plunges on Failure of Late-Stage Study on Molgradex
by Zacks Equity Research
Savara's (SVRA) lead pipeline candidate, Molgradex, fails to meet primary endpoint in a phase III study evaluating it in a rare autoimmune lung disorder.
Implied Volatility Surging for Savara (SVRA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.
Savara Inc (SVRA) Upgraded to Buy: Here's Why
by Zacks Equity Research
Savara Inc (SVRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Savara Inc (SVRA) Upgraded to Buy: Here's Why
by Zacks Equity Research
Savara Inc (SVRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).